| Date: | | July 13,2022 | | | | |
|------------------|---------------------------|-------------------------|-------------------|-----------------|----------------|--------------|
| Your Name: | Qianqian Si | | | | | |
| Manuscript Title | e: Disease effects of int | tracranial atherosclero | tic stenosis: stu | dy protocol for | a multicenter, | prospective, |
| observational co | ohort study | | | | | |
| Manuscript num | nber (if known): | | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|------------------|------------------------------|----------------------|----------------------|------------------|--------------------------|
| Your Name: | Yuming Teng | | | | |
| Manuscript Title | e: Disease effects of intrac | cranial atherosclero | ic stenosis: study p | rotocol for a mu | ulticenter, prospective, |
| observational co | ohort study | | | | |
| Manuscript num | nber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | √None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | v None v None | |
| 2 | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √ None | |
| | , | | |
| | | | |
| 4 | Consulting fees | √None | |
| | _ | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|------------------|--------------------------|--------------------------|---------------------------|-------------------------|--------------|
| Your Name: | Caiyan Liu | | | | |
| Manuscript Title | e: Disease effects of ir | ntracranial atherosclero | tic stenosis: study proto | ocol for a multicenter, | prospective, |
| observational c | ohort study | | | | |
| Manuscript nur | nber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | |
|------------------|----------------------------|--|--------------------------------|
| Your Name: | Weizhuang Yuan | | |
| Manuscript Title | : Disease effects of intra | cranial atherosclerotic stenosis: study protocol f | or a multicenter, prospective, |
| observational co | hort study | | |
| Manuscript num | ber (if known): | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | √None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | v None v None | |
| 2 | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √ None | |
| | , | | |
| | | | |
| 4 | Consulting fees | √None | |
| | _ | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | |
|------------------|---------------------------|--------------------------------|---|--------|
| Your Name: | Xiaoyuan Fan | | | |
| Manuscript Title | e: Disease effects of int | racranial atherosclerotic ster | enosis: study protocol for a multicenter, prospec | ctive, |
| observational co | ohort study | | | |
| Manuscript num | nber (if known): | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present | | |
| 1 | All support for the present manuscript (e.g., funding, | √None | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | VNone | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | _July 13,2022 | |
|------------------|----------------------------|--------------------------------|---|
| Your Name: | Xiaoqian Zhang | | |
| Manuscript Title | e: Disease effects of intr | acranial atherosclerotic steno | sis: study protocol for a multicenter, prospective, |
| observational co | ohort study | | |
| Manuscript num | nber (if known): | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | √None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | v None v None | |
| 2 | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √ None | |
| | , | | |
| | | | |
| 4 | Consulting fees | √None | |
| | _ | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | Ju | uly 13,2022 | | | |
|------------------|-------------------------------|-----------------------|------------------------|------------------------|------------------|
| Your Name: | Zongmuyu Zhang | | | | |
| Manuscript Title | e: Disease effects of intracr | anial atherosclerotic | c stenosis: study prot | cocol for a multicente | er, prospective, |
| observational co | ohort study | | | | |
| Manuscript num | ber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | √None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | v None v None | |
| 2 | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √ None | |
| | , | | |
| | | | |
| 4 | Consulting fees | √None | |
| | _ | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | July 13,2022 | |
|------------------|---|--------|
| Your Name: | _Mingli Li | |
| Manuscript Title | sease effects of intracranial atherosclerotic stenosis: study protocol for a multicenter, prospec | ctive, |
| observational co | t study | |
| Manuscript num | (if known): | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | _ |
|------------------|------------------------|--------------------------|---------------------------|-----------------------|-----------------|
| Your Name: | Qing Liu | | | | |
| Manuscript Title | : Disease effects of i | ntracranial atherosclero | tic stenosis: study proto | ocol for a multicente | r, prospective, |
| observational co | hort study | | | | |
| Manuscript num | ber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|------------------|--------------------------|---------------------------|---------------------|-------------------|-------------------------|
| Your Name: | Peng Wang | | | | |
| Manuscript Title | e: Disease effects of in | tracranial atheroscleroti | c stenosis: study p | protocol for a mu | lticenter, prospective, |
| observational co | ohort study | | | | |
| Manuscript num | nber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present | | |
| 1 | All support for the present manuscript (e.g., funding, | √None | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | VNone | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|-----------------|---------------------------|------------------------------|---------------------------|-------------------------------|----|
| Your Name: | Zhongrui Yan | | | | |
| Manuscript Titl | e: Disease effects of int | tracranial atherosclerotic s | tenosis: study protocol f | or a multicenter, prospective | e, |
| observational c | ohort study | | | | |
| Manuscript nui | mber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|------------------|-----------------------|------------------------------|--------------------------|------------------------|--------------|
| Your Name: | Bo Wu | | | | |
| Manuscript Title | e: Disease effects of | f intracranial atherosclerot | ic stenosis: study proto | col for a multicenter, | prospective, |
| observational co | ohort study | | | | |
| Manuscript nun | nber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | | |
|------------------|-----------------------|---------------------------|------------------------------|------------------|-----------------|------------|
| Your Name: | Qiang Liu | | | | | |
| Manuscript Title | e: Disease effects of | intracranial atherosclero | tic stenosis: study j | protocol for a n | nulticenter, pr | ospective, |
| observational co | ohort study | | | | | |
| Manuscript num | nber (if known): | | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | | |
|------------------|--------------------------|-------------------------|-------------------|-----------------|----------------|--------------|
| Your Name: | Hangjuan Li | | | | | |
| Manuscript Title | : Disease effects of int | tracranial atherosclero | tic stenosis: stu | dy protocol for | a multicenter, | prospective, |
| observational co | hort study | | | | _ | |
| Manuscript num | ber (if known): | | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|------------------|--------------------------|-------------------------|---------------------------|-------------------------|--------------|
| Your Name: | Yan Ji | | | | |
| Manuscript Title | e: Disease effects of in | tracranial atherosclero | tic stenosis: study proto | ocol for a multicenter, | prospective, |
| observational co | ohort study | | | | |
| Manuscript num | nber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | | |
| - | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | VNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|------------------|--------------------------|----------------------------|-----------------------|---------------------|---------------------|
| Your Name: | Yuncai Ran | | | | |
| Manuscript Title | e: Disease effects of in | ntracranial atheroscleroti | c stenosis: study pro | otocol for a multic | enter, prospective, |
| observational co | ohort study | | | | |
| Manuscript num | nber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present | | |
| T | All support for the present manuscript (e.g., funding, | √None | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | VNone | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | VNone | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|------------------|----------------------|-----------------------------|----------------------------|-------------------------------|-----|
| Your Name: | Bo Song | | | | |
| Manuscript Title | : Disease effects of | intracranial atheroscleroti | c stenosis: study protocol | for a multicenter, prospectiv | ve, |
| observational co | hort study | | | | |
| Manuscript num | ber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|------------------|--------------------------|-------------------------|------------------------|------------------------|------------------|
| Your Name: | Shiguang Zhu | | | | |
| Manuscript Title | : Disease effects of int | racranial atherosclerot | ic stenosis: study pro | otocol for a multicent | er, prospective, |
| observational co | hort study | | | | |
| Manuscript num | ber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | | |
|------------------|---------------------------|------------------------|---------------------|------------------|-----------------|-------------|
| Your Name: | Hongyan Li | | | | | _ |
| Manuscript Title | e: Disease effects of int | racranial atherosclero | tic stenosis: study | / protocol for a | multicenter, pr | rospective, |
| observational co | ohort study | | | | _ | |
| Manuscript num | nber (if known): | | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present | | |
| T | All support for the present manuscript (e.g., funding, | √None | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | VNone | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | VNone | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | | |
|------------------|---------------------------|--------------------------|---------------------|----------------|------------------|-------------|
| Your Name: | Jingxia Guan | | | | | |
| Manuscript Title | e: Disease effects of int | tracranial atherosclerot | tic stenosis: study | protocol for a | ı multicenter, p | rospective, |
| observational co | ohort study | | | | | |
| Manuscript nun | nber (if known): | | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
| | r F | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | |
|------------------|--------------------------|--|------------------------------------|
| Your Name: | Manli Zhao | | |
| Manuscript Title | e: Disease effects of in | tracranial atherosclerotic stenosis: study protoco | ol for a multicenter, prospective, |
| observational co | ohort study | | |
| Manuscript num | nber (if known): | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | | |
|------------------|---------------------------|------------------------|---------------------|------------------|--------------------|---------|
| Your Name: | Yonggang Hao | | | | | _ |
| Manuscript Title | e: Disease effects of int | racranial atherosclero | tic stenosis: study | y protocol for a | multicenter, prosp | ective, |
| observational co | ohort study | | | | | |
| Manuscript num | nber (if known): | | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | |
|------------------|---------------------------|------------------------------|---------------------------|--------------------------------|
| Your Name: | Pengfei Wang | | | |
| Manuscript Title | e: Disease effects of int | racranial atherosclerotic st | enosis: study protocol fo | or a multicenter, prospective, |
| observational co | ohort study | | | |
| Manuscript num | nber (if known): | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|------------------|-------------------------|---------------------------|--------------------------|--------------------------|----------------|
| Your Name: | Hong Bian | | | | |
| Manuscript Title | e: Disease effects of i | intracranial atherosclero | otic stenosis: study pro | tocol for a multicenter, | , prospective, |
| observational co | ohort study | | | | |
| Manuscript nun | nber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | |
|------------------|----------------------------|----------------------------|-------------------------|---------------------------------|
| Your Name: | Ningfen Wang | | | |
| Manuscript Title | e: Disease effects of intr | acranial atherosclerotic s | tenosis: study protocol | for a multicenter, prospective, |
| observational co | ohort study | | | |
| Manuscript num | nber (if known): | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | _July 13,2022 | | | |
|-----------------|-----------------------------|--------------------------|-----------------------|--------------------------|--------------|
| Your Name: | Yulin Wang | | | | _ |
| Manuscript Titl | e: Disease effects of intra | acranial atherosclerotic | stenosis: study proto | col for a multicenter, p | prospective, |
| observational c | ohort study | | | | |
| Manuscript nur | nber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|-------------------|-----------------------|------------------------------|-------------------------|-----------------------|------------|
| Your Name: | Yuning Pan | | | | |
| Manuscript Title: | Disease effects of in | tracranial atherosclerotic s | tenosis: study protocol | for a multicenter, pr | ospective, |
| observational col | hort study | | | | |
| Manuscript num | ber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|------------------|--------------------------|--------------------------|--------------------------|------------------------|--------------|
| Your Name: | Hongwei An | | | | |
| Manuscript Title | : Disease effects of int | tracranial atherosclerot | ic stenosis: study proto | col for a multicenter, | prospective, |
| observational co | hort study | | | | |
| Manuscript num | ber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|-------------------|----------------------|----------------------------|---------------------------|-----------------------|--------------|
| Your Name: | Rong Guo | | | | _ |
| Manuscript Title: | Disease effects of i | ntracranial atheroscleroti | c stenosis: study protoco | ol for a multicenter, | prospective, |
| observational coh | ort study | | | | |
| Manuscript numb | er (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
| | r F | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|-------------------|-------------------------|---------------------------|-----------------------------|-----------------------|----------------------|
| Your Name: | Cong Han | | | | |
| Manuscript Title: | : Disease effects of in | ntracranial atherosclerot | ic stenosis: study j | protocol for a multic | center, prospective, |
| observational co | hort study | | | | |
| Manuscript num | ber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|-----------------|----------------------------|------------------------|------------------------|-----------------------|-------------------|
| Your Name: | Junshi Zhang | | | | |
| Manuscript Titl | le: Disease effects of int | racranial atherosclero | ic stenosis: study pro | tocol for a multicent | ter, prospective, |
| observational o | ohort study | | | | |
| Manuscript nui | mber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | |
|------------------|-------------------------|--|--|
| Your Name: | Hebo Wang | | |
| Manuscript Title | : Disease effects of ir | tracranial atherosclerotic stenosis: study | y protocol for a multicenter, prospective, |
| observational co | hort study | | |
| Manuscript num | ber (if known): | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|-------------------|--------------------|---------------------------|-------------------------|-------------------------|------------------|
| Your Name: | Yong You | | | | |
| Manuscript Title: | Disease effects of | intracranial atherosclere | otic stenosis: study pr | rotocol for a multicent | er, prospective, |
| observational co | hort study | | | | |
| Manuscript num | ber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | Jul | ly 13,2022 | | | | _ |
|------------------|--------------------------------|--------------------|-------------------|-----------------|-----------------|-----------------|
| Your Name: | Hongquan Jiang | | | | | |
| Manuscript Title | e: Disease effects of intracra | inial atherosclero | otic stenosis: st | udy protocol fo | or a multicente | r, prospective, |
| observational co | ohort study | | | | | |
| Manuscript nun | nber (if known): | | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|------------------|----------------------|---------------------------|---------------------|---------------------|-----------------------|
| Your Name: | Zifan Liu | | | | |
| Manuscript Title | : Disease effects of | intracranial atherosclero | tic stenosis: study | protocol for a mult | icenter, prospective, |
| observational co | hort study | | | | |
| Manuscript num | ber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | |
|------------------|------------------------|--------------------------|-----------------------------|-----------------------------------|
| Your Name: | Jingli Liu | | | |
| Manuscript Title | : Disease effects of i | ntracranial atherosclero | tic stenosis: study protoco | I for a multicenter, prospective, |
| observational co | hort study | | | |
| Manuscript num | ber (if known): | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|-------------------|------------------------|---------------------------|-------------------------|-----------------------|--------------|
| Your Name: | Dingbo Tao | | | | _ |
| Manuscript Title: | Disease effects of int | racranial atherosclerotic | stenosis: study protoco | ol for a multicenter, | prospective, |
| observational co | hort study | | | | |
| Manuscript num | ber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|------------------|--------------------------|-------------------------|-------------------------|-------------------------|------------------|
| Your Name: | Xiangyu Piao | | | | |
| Manuscript Title | e: Disease effects of in | tracranial atherosclero | tic stenosis: study pro | otocol for a multicente | er, prospective, |
| observational co | ohort study | | | | |
| Manuscript nun | nber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 4 | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | _July 13,2022 | | | | |
|------------------|-----------------------------|----------------------|-------------------|-------------------------------|------------------|--------------|
| Your Name: | Jiangtao Zhang | | | | | |
| Manuscript Title | e: Disease effects of intra | acranial atheroscler | otic stenosis: st | u <mark>dy protocol</mark> fo | r a multicenter, | prospective, |
| observational co | ohort study | | | | | |
| Manuscript nun | nber (if known): | | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | |
|-------------------|-----------------------|--|--------------|
| Your Name: | Pei Wang | | |
| Manuscript Title: | Disease effects of in | tracranial atherosclerotic stenosis: study protocol for a multicenter, | prospective, |
| observational col | nort study | | |
| Manuscript numb | per (if known): | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | |
|------------------|-------------------------|--|---|
| Your Name: | Shen Yang | | |
| Manuscript Title | : Disease effects of ir | tracranial atherosclerotic stenosis: study p | rotocol for a multicenter, prospective, |
| observational co | hort study | | |
| Manuscript num | ber (if known): | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | |
|------------------|------------------------|---------------------------------------|---|
| Your Name: | Zhou Liu | | |
| Manuscript Title | : Disease effects of i | ntracranial atherosclerotic stenosis: | s: study protocol for a multicenter, prospective, |
| observational co | hort study | | |
| Manuscript num | ber (if known): | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
| | r F | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | _ |
|-------------------|----------------------|-----------------------------|----------------------|------------------------|-----------------------------|
| Your Name: | Xiue Wei | | | | |
| Manuscript Title: | Disease effects of i | ntracranial atherosclerotic | stenosis: study prot | ocol for a multicenter | [,] , prospective, |
| observational col | hort study | | | | |
| Manuscript num | ber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present | | |
| 1 | All support for the present manuscript (e.g., funding, | √None | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | VNone | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | |
|-------------------|-------------------|-------------------------------|------------------------------|---------------------------------|
| Your Name: | Kai Han | | | |
| Manuscript Title: | Disease effects o | f intracranial atheroscleroti | c stenosis: study protocol f | for a multicenter, prospective, |
| observational col | nort study | | | |
| Manuscript numb | per (if known): | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
| | r F | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | |
|-------------------|----------------------|---|---|
| Your Name: | Zhimin Shi | | |
| Manuscript Title: | Disease effects of i | ntracranial atherosclerotic stenosis: stu | dy protocol for a multicenter, prospective, |
| observational col | hort study | | |
| Manuscript numl | ber (if known): | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|-------------------|--------------------|---------------------------|-------------------------|-------------------------|-------------------|
| Your Name: | Aihua Liu | | | | |
| Manuscript Title: | Disease effects of | intracranial atherosclero | otic stenosis: study pr | rotocol for a multicent | ter, prospective, |
| observational col | hort study | | | | |
| Manuscript numl | ber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
| | r F | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | _July 13,2022 | |
|------------------|--------------------------|---|----------|
| Your Name: | Zuowen Zhang | | |
| Manuscript Title | : Disease effects of int | cranial atherosclerotic stenosis: study protocol for a multicenter, prosp | oective, |
| observational co | hort study | | |
| Manuscript num | ber (if known): | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | |
|-------------------|------------------------|------------------------------|------------------------------|-------------------------------|
| Your Name: | Chunye Ma | | | |
| Manuscript Title: | Disease effects of int | tracranial atherosclerotic s | stenosis: study protocol for | r a multicenter, prospective, |
| observational col | hort study | | | |
| Manuscript numl | ber (if known): | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | _July 13,2022 | |
|------------------|--------------------------|---|-----------|
| Your Name: | Baichen Wang | | |
| Manuscript Title | : Disease effects of int | acranial atherosclerotic stenosis: study protocol for a multicenter, pros | spective, |
| observational co | hort study | | |
| Manuscript num | ber (if known): | | _ |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | _July 13,2022 | |
|------------------|----------------------------|--------------------------------|--|
| Your Name: | Gejuan Zhang | | |
| Manuscript Title | e: Disease effects of intr | acranial atherosclerotic stend | nosis: study protocol for a multicenter, prospective |
| observational co | ohort study | | |
| Manuscript num | nber (if known): | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | Jul | ly 13,2022 | | | | |
|------------------|--------------------------------|----------------------|-----------------|-----------------|--------------------|------------|
| Your Name: | Chengguang Song | | | | | |
| Manuscript Title | e: Disease effects of intracra | inial atheroscleroti | c stenosis: stu | dy protocol for | a multicenter, pro | ospective, |
| observational co | ohort study | | | | | |
| Manuscript nun | nber (if known): | | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | |
|------------------|---------------------------|------------------------------|----------------------------|--------------------------------|
| Your Name: | Guilian Zhang | | | |
| Manuscript Title | e: Disease effects of int | racranial atherosclerotic st | tenosis: study protocol fo | or a multicenter, prospective, |
| observational co | ohort study | | | |
| Manuscript num | nber (if known): | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | |
|-------------------|----------------------|--|----------------|
| Your Name: | Xiao Yang | | |
| Manuscript Title: | Disease effects of i | intracranial atherosclerotic stenosis: study protocol for a multicenter, | , prospective, |
| observational col | ort study | | |
| Manuscript numb | per (if known): | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|------------------|------------------------|--------------------------|-----------------------|---------------------------|------------------|
| Your Name: | Bing Chen | | | | |
| Manuscript Title | : Disease effects of i | ntracranial atherosclero | tic stenosis: study p | protocol for a multicente | er, prospective, |
| observational co | hort study | | | | |
| Manuscript num | ber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | _ |
|-------------------|-----------------------|-----------------------------|-----------------------|-----------------------|-----------------|
| Your Name: | Baoquan Lu | | | | |
| Manuscript Title: | Disease effects of in | ntracranial atherosclerotic | stenosis: study proto | col for a multicenter | r, prospective, |
| observational col | ort study | | | | |
| Manuscript numb | er (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | |
|-------------------|-----------------------|---|--------------|
| Your Name: | Beilei Chen | | |
| Manuscript Title: | Disease effects of in | ntracranial atherosclerotic stenosis: study protocol for a multicenter, I | prospective, |
| observational col | hort study | | |
| Manuscript numl | ber (if known): | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|------------------|------------------------|--------------------------|--------------------------|------------------------|----------------|
| Your Name: | Meng Zuo | | | | |
| Manuscript Title | : Disease effects of i | ntracranial atherosclero | tic stenosis: study prot | ocol for a multicenter | , prospective, |
| observational co | hort study | | | | |
| Manuscript num | ber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|-------------------|----------------------|---------------------------|-----------------------|-------------------------|--------------------|
| Your Name: | Kun Han | | | | |
| Manuscript Title: | : Disease effects of | intracranial atherosclero | tic stenosis: study p | protocol for a multicer | nter, prospective, |
| observational co | hort study | | | | |
| Manuscript num | ber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
| | r F | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | _July 13,2022 | | | _ |
|------------------|----------------------------|----------------------------|-----------------------|-----------------------|-----------------|
| Your Name: | Xiaodan Zhang | | | | |
| Manuscript Title | e: Disease effects of intr | acranial atherosclerotic s | stenosis: study proto | col for a multicenter | r, prospective, |
| observational co | ohort study | | | | |
| Manuscript num | nber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|------------------|--------------------------|------------------------------|------------------------|-------------------------|--------------|
| Your Name: | Wenfeng Cao | | | | |
| Manuscript Title | : Disease effects of int | racranial atherosclerotic st | tenosis: study protoco | ol for a multicenter, p | prospective, |
| observational co | hort study | | | | |
| Manuscript num | ber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | |
|------------------|---------------------------|------------------------------|----------------------------|-----------------------------|
| Your Name: | Lingfeng Wu | | | |
| Manuscript Title | e: Disease effects of int | racranial atherosclerotic st | enosis: study protocol for | a multicenter, prospective, |
| observational c | ohort study | | | _ |
| Manuscript nun | nber (if known): | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | July | / 13,2022 | |
|------------------|---------------------------------|--------------------------------|--|
| Your Name: | Qi Li | | |
| Manuscript Title | e: Disease effects of intracran | nial atherosclerotic stenosis: | study protocol for a multicenter, prospective, |
| observational co | ohort study | | |
| Manuscript nun | nber (if known): | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | VNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | |
|------------------|--------------------------|-------------------------------|--|------------|
| Your Name: | Xiaokun Geng | | | |
| Manuscript Title | : Disease effects of int | racranial atherosclerotic ste | tenosis: study protocol for a multicenter, pro | ospective, |
| observational co | hort study | | | |
| Manuscript num | ber (if known): | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | |
|------------------|---------------------------|------------------------------|-----------------------------|-----------------------------|
| Your Name: | Junshan Zhou | | | |
| Manuscript Title | e: Disease effects of int | racranial atherosclerotic st | tenosis: study protocol for | a multicenter, prospective, |
| observational co | ohort study | | | |
| Manuscript num | nber (if known): | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | | |
|------------------|-----------------------------|----------------------|--------------------|------------------|------------------|------------|
| Your Name: | Mengfei Zhong | | | | | |
| Manuscript Title | e: Disease effects of intra | cranial atherosclero | tic stenosis: stud | y protocol for a | multicenter, pro | ospective, |
| observational co | ohort study | | | | | |
| Manuscript nun | nber (if known): | | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | _July 13,2022 | | | | |
|------------------|-----------------------------|--------------------|--------------------|------------------|-------------------|--------------|
| Your Name: | Minghua Wang | | | | | |
| Manuscript Title | e: Disease effects of intra | cranial atheroscle | rotic stenosis: st | tudy protocol fc | or a multicenter, | prospective, |
| observational co | ohort study | | | | | |
| Manuscript nun | nber (if known): | | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | _July 13,2022 | |
|------------------|---------------------------|--|---|
| Your Name: | Yangmei Chen | | |
| Manuscript Title | e: Disease effects of int | acranial atherosclerotic stenosis: study p | rotocol for a multicenter, prospective, |
| observational co | ohort study | | |
| Manuscript num | ber (if known): | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 |
|------------------|------------------------|--|
| Your Name: | Jiachun Liu | |
| Manuscript Title | : Disease effects of i | tracranial atherosclerotic stenosis: study protocol for a multicenter, |
| prospective, obs | ervational cohort stu | dy |
| Manuscript num | ber (if known): | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | | |
|------------------|---------------------------|-----------------------|---------------------|------------------|------------------|-----------|
| Your Name: | Tingrui Wang | | | | | |
| Manuscript Title | e: Disease effects of int | racranial atheroscler | otic stenosis: stud | y protocol for a | multicenter, pro | spective, |
| observational co | ohort study | | | | | |
| Manuscript nun | nber (if known): | | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | | | |
|------------------|----------------------------|------------------------|----------------------|-----------------|---------------------------|
| Your Name: | Youqing Deng | | | | |
| Manuscript Title | e: Disease effects of intr | acranial atherosclerot | ic stenosis: study p | rotocol for a m | nulticenter, prospective, |
| observational co | ohort study | | | | |
| Manuscript nun | nber (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | | |
| 1 | All support for the present | VNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | | July 13,2022 | _ |
|-------------------|-----------------------|---|-----------------|
| Your Name: | Weihai Xu | | _ |
| Manuscript Title: | Disease effects of in | ntracranial atherosclerotic stenosis: study protocol for a multicente | r, prospective, |
| observational col | hort study | | |
| Manuscript num | ber (if known): | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) | | |
|---|--|---|---|--|--|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | | | |
| | Time frame: past 36 months | | | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | vNone | | | |
| 3 | Royalties or licenses | √None | | | |
| 4 | Consulting fees | √None | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | √None |
|----|---|-------|
| 7 | Support for attending meetings and/or travel | VNone |
| | - | |
| 8 | Patents planned, issued or pending | VNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | VNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | VNone |
| 11 | Stock or stock options | VNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | VNone |
| 13 | Other financial or non- financial interests | VNone |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement: